- Previous Close
2,427.85 - Open
2,427.85 - Bid 2,440.20 x --
- Ask 2,446.00 x --
- Day's Range
2,404.05 - 2,463.95 - 52 Week Range
1,910.10 - 3,050.00 - Volume
29,598 - Avg. Volume
13,890 - Market Cap (intraday)
1.006T - Beta (5Y Monthly) --
- PE Ratio (TTM)
48.10 - EPS (TTM)
50.72 - Earnings Date Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2,797.82
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.
www.mankindpharma.com19,540
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: MANKIND.BO
View MorePerformance Overview: MANKIND.BO
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MANKIND.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MANKIND.BO
View MoreValuation Measures
Market Cap
1.01T
Enterprise Value
968.25B
Trailing P/E
48.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.46
Price/Book (mrq)
9.57
Enterprise Value/Revenue
8.32
Enterprise Value/EBITDA
28.99
Financial Highlights
Profitability and Income Statement
Profit Margin
17.54%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
116.41B
Net Income Avi to Common (ttm)
20.41B
Diluted EPS (ttm)
50.72
Balance Sheet and Cash Flow
Total Cash (mrq)
47.27B
Total Debt/Equity (mrq)
4.47%
Levered Free Cash Flow (ttm)
--